Enzyme | Affected Drug | Affected Property | Overall Effect |
---|---|---|---|
ALDH | Acetaldehyde | PK | ↑ AUC, Cmax |
Ethanol | PD | ↑ Facial skin blood flow, heart rate | |
AO | XK-469 | PK | ↓ Clearance |
CES (CES1 or CES2) | Clopidogrel | PK | ↑ AUC, Cmax; ↓ metabolite/parent |
Enalaprilat | PD | ↓ Maximum platelet aggregation | |
Oseltamivir | PK | ↓ AUC | |
PK | ↑ AUC, Cmax; ↓ metabolite/parent | ||
Carbonyl reductase | Daunorubicin | PK | ↑ AUC; ↓ clearance |
Catechol-O-methyltransferase | MDMA | PD | ↓ Blood pressure |
Paliperidone | PK | ↓ AUC | |
Epoxide hydrolase | Carbamazepine | PK | ↑ Dose |
Warfarin | PK | ↓ Dose | |
FMO | Danusertib | PK | ↑ Clearance |
Itopride | PK | ↑ AUC, Cmax; ↓ clearance | |
Sulindac sulfide | PK | ↑ AUC | |
N-Acetyltransferase | N-Acetylretigabine | PK | ↓ AUC |
Sulfapyridine | PK | ↑ AUC | |
Sulfamethoxazole | PK | ↑ AUC | |
Isoniazid | PK | ↑ AUC | |
Phenytoin | PK | ↑ AUC, Cmax; ↓ clearance |
The University of Washington Drug Interaction Database is available at https://didb.druginteractioninfo.org (accessed May 10, 2016). AUC, area under the curve; MDMA, 3,4-methylenedioxymethamphetamine; PD, pharmacodynamics; PK, pharmacokinetics; UDPGA, UDP glucuronic acid; XK-469, 2-(4-((7-chloro-2-quinoxalinyl)oxy)phenoxy)propionic acid. Increases and decreases in overall effect parameters are indicated by up and down arrows, respectively.